Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
EUCR was delisted on the 26th of April, 2023.
39 hedge funds and large institutions have $73.2M invested in Eucrates Biomedical Acquisition Corp. Ordinary Shares in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 4 closing their positions.
160% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 5
13% more capital invested
Capital invested by funds: $64.6M → $73.2M (+$8.59M)
0% more funds holding
Funds holding: 39 → 39 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$5.09M |
| 2 |
SCM
Saba Capital Management
New York
|
+$2.1M |
| 3 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$777K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$777K |
| 5 |
SC
Sculptor Capital
New York
|
+$751K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
-$976K |
| 2 |
HIH
HRS Investment Holdings
New York
|
-$722K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$443K |
| 4 |
Millennium Management
New York
|
-$307K |
| 5 |
DFCM
Dark Forest Capital Management
San Juan,
Puerto Rico
|
-$239K |
EUCR Hedge Fund Activity: Q1 2022 in Review
39 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q1 2022, worth a combined $73.2M — up 13% from $64.6M a quarter earlier.
Fund positioning in EUCR was balanced in Q1 2022: 4 funds opened new positions, 4 closed out, 13 added to existing stakes and 5 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $5.09M. The largest seller was Arena Capital Advisors, exiting entirely with an estimated $976K sold.
- 39 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $73.2M of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q1 2022, up 13% quarter-over-quarter.
- 4 funds opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q1 2022 and 4 closed out, a net change of 0 holders.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares buyer in Q1 2022 was Goldman Sachs, an estimated $5.09M added.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares seller in Q1 2022 was Arena Capital Advisors, an estimated $976K sold.
Based on aggregated 13F filings for Q1 2022.